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OBJECTIVES We sought to test whether tetrahydrobiopterin (BH4) supplementation improves nitric oxide
(NO) bioactivity in smokers.
BACKGROUND In smokers, endothelium-derived NO bioactivity is impaired. BH4 is an essential cofactor of
NO synthase, and its deficiency decreases NO bioactivity.
METHODS Sapropterin hydrochloride, an active analogue of BH4 (2 mg/kg body weight), was
administered orally to healthy male smokers and age-matched nonsmokers. Before and 3 and
24 h after sapropterin, we measured plasma levels of BH4 and examined flow-mediated
vasodilation (FMV) of the brachial artery by high resolution ultrasonography, a noninvasive
test of endothelial function.
RESULTS Basal plasma levels of BH4 were not different between smokers and nonsmokers. Sapropterin
administration increased plasma levels of BH4 by threefold at 3 h, which returned to the
baseline at 24 h. Before sapropterin, FMV was significantly smaller in smokers (p 5 0.0002).
Sapropterin significantly augmented endothelium-dependent vasodilation in smokers, but did
not affect it in nonsmokers (p 5 0.001 by analysis of variance [ANOVA]). Coadministration
of NG-monomethyl-L-arginine (L-NMMA), an NO synthase inhibitor (20 mmol), into the
brachial artery completely abolished the vasodilatory effects of sapropterin (p 5 0.002 by
ANOVA). Endothelium-independent vasodilation by glyceryl trinitrate was not different
between smokers and nonsmokers and was not altered by BH4.
CONCLUSIONS We demonstrated that BH4 supplementation improved bioactivity of endothelium-derived
NO in smokers. These observations strongly suggest that decreased NO-dependent vasodi-
lation in smokers could be related to reduced bioactivity of BH4. (J Am Coll Cardiol 2000;
35:71–5) © 1999 by the American College of Cardiology
During the formation of nitric oxide (NO) and L-citrulline,
nitric oxide synthase (NOS) requires several cofactors,
including NADPH, calcium-calmodulin, flavin nucleotides
and tetrahydrobiopterin (BH4) (1,2). Among these cofac-
tors, BH4 plays a crucial role in the regulation of NOS
activity. Depletion of BH4 causes uncoupling of the L-
arginine–NO pathway, which results in decreased formation
of NO and increased formation of oxygen radicals by NOS
in vitro (3,4). Recent reports have demonstrated that exog-
enous administration of BH4 restores impaired NO bioac-
tivity in hypercholesterolemic humans (5) and hypertensive
rats (6), suggesting the relative depletion of BH4 in the
presence of coronary risk factors.
It has been suggested that decreased bioactivity of
endothelium-derived NO through oxidative stress is re-
sponsible for endothelial dysfunction in smokers (2,7,8).
Although the precise mechanisms are unknown, dysregula-
tion of BH4 may be involved. Higman et al. (9) demon-
strated that exogenous BH4 improved endothelium-
dependent vasodilation of saphenous vein strips from
smokers. However, because this experiment was conducted
ex vivo using vein strips, the in vivo effects of BH4 on
arterial endothelial dysfunction in smokers need to be
elucidated.
In this study, we examined the effects of exogenous BH4
on endothelium-dependent vasodilation in the brachial
artery in long-term smokers in the presence or absence of an
NOS inhibitor.
METHODS
Subjects. Studies were performed in 17 healthy male vol-
unteers (10 smokers and 7 nonsmokers). None had clinical
signs of atherosclerosis on physical examination. Smokers
were defined as current smokers consuming at least 20
cigarettes per day (28.6 6 2.0 cigarettes per day, range 20 to
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40) for one year or more (11.6 6 1.7 years, range 5 to 22),
and their smoking status was confirmed by measurement of
plasma cotinine (0.10 6 0.03 mg/ml vs. undetected). Age-
matched control subjects were life-long nonsmokers (30 6
2 vs. 29 6 1 years old, p 5 NS). All subjects were not obese
(body mass index: 22 6 1 vs. 23 6 1 kg/m2, p 5 NS),
normotensive (mean arterial pressure: 84 6 2 vs. 84 6
2 mm Hg, p 5 NS), nondiabetic (fasting plasma glucose:
94 6 5 vs. 98 6 2 mg/dl, p 5 NS; glycosylated hemoglobin
[HbA1c]: 4.7 6 0.4% vs. 5.0 6 0.4%, p 5 NS) and
normolipidemic (total cholesterol: 182 6 9 vs. 178 6
10 mg/dl, p 5 NS; low density lipoprotein [LDL] choles-
terol: 108 6 9 vs. 109.8 6 8 mg/dl, p 5 NS; high density
lipoprotein [HDL] cholesterol: 51 6 3 vs. 51 6 3 mg/dl,
p 5 NS; triglycerides: 115 6 22 vs. 89 6 23 mg/dl, p 5
NS), and there were no significant differences between
smokers and nonsmokers in other backgrounds. The sub-
jects had not taken any medications before the experiment.
Study design. The protocol was explained, and written
informed consent was obtained from each subject. The
study was approved by the Ethical Committee for Human
Investigation at our institution. The study was performed in
the morning after the subjects had fasted overnight in a
supine position in an air-conditioned room with room
temperature ;25°C. Smokers had abstained from smoking
for .120 min before the start of the experiments to avoid
the short-term effects of smoking. The fasting blood level
was drawn for measurement of plasma cotinine and BH4.
We measured blood pressure, heart rate, endothelial func-
tion and plasma levels of BH4 before and 3 and 24 h after
oral administration of sapropterin hydrochloride, an active
form of BH4 (2 mg/kg body weight, Biopten, Suntory,
Tokyo). To examine the possible relation between NO and
the effects of BH4, in separate occasions under pretreatment
with NG-monomethyl-L-arginine (L-NMMA) (Clinalfa,
Switzerland), a NOS inhibitor, we repeated blood sampling
and measurement of vascular function before and 3 h after
oral administration of sapropterin hydrochloride in smokers.
L-NMMA was infused into the brachial artery with a
22-gauge catheter, placed at least 3 cm proximal to the
probe of ultrasonography at a dose of 4 mmol/min for 5 min
(20 mmol in total), 15 min before measurement of endo-
thelial function. The catheter was pulled out after infusion.
Subjects were not allowed to eat until the 3-h experiment
was finished, and measurements at 24-h were conducted
after overnight fasting to avoid the effects of diet.
Measurement of endothelial function. With the use of
high resolution ultrasonography (SSA-380A, Toshiba, To-
kyo), the brachial artery was imaged longitudinally just
above the antecubital fossa, three times at baseline, and then
scanned continuously for 15 min after release of 4.5 min of
upper arm arterial occlusion with a 12.5-cm-wide blood
pressure cuff that was placed 3 to 5 cm proximal to the
studied part (10). To assess endothelium-independent va-
sodilation, sublingual glyceryl trinitrate (GTN)-induced
(300 mg; Myocol Spray, Toa Eiyo Co., Tokyo, Japan)
vasodilation was examined. Measurements were conducted
in a blinded manner and the interobservational and intraob-
servational variations of the baseline measurements were
2.8% and 1.6%, respectively.
Chemical analysis. Serum total cholesterol and triglyceride
levels were determined enzymatically with commercial kits
(L-type Wako cholesterol, L-type Wako TG-H, respec-
tively; Wako Chemicals Co., Osaka, Japan). High density
lipoprotein cholesterol was determined by homogeneous
HDL cholesterol assay with commercial kits (Cholesterol
HDL; Daiichi Chemicals Co., Tokyo, Japan). Low density
lipoprotein cholesterol was calculated by the Friedewald
formula. Plasma glucose was measured by the glucose
dehydrogenase ultraviolet test (Merck Liquid Glu; Kanto
Chemical Co., Tokyo, Japan). Then HbA1c was measured
by latex agglutination turbidimetry with a commercial kit
(Rapidia Auto HbA1c; Fujirebio Inc., Tokyo, Japan). Tet-
rahydrobiopterin was measured by high performance liquid
chromatography with the electrochemical detection
method, as previously described (11). Cotinine was mea-
sured by high performance liquid chromatography.
Statistical analysis. Statistical comparisons were per-
formed by two-way analysis of variance (ANOVA) for
repeated measures, followed by Bonferroni post hoc analysis
for changes in endothelial function and chemical variables
before and after BH4 loading. All data are expressed as the
mean value 6 SEM, and p , 0.05 was considered to be
statistically significant.
RESULTS
Vascular function at baseline. For the baseline vessel
diameter of the brachial artery there was no significant
difference between smokers and nonsmokers (Table 1).
Flow-mediated vasodilation (FMV) of the brachial artery at
baseline was significantly smaller in smokers (p 5 0.0002,
Fig. 1, top). Glyceryl trinitrate–induced brachial artery
dilation (p 5 NS, Fig. 1, bottom) and the magnitude of
Abbreviations and Acronyms
ANOVA 5 analysis of variance
BH4 5 tetrahydrobiopterin
FMV 5 flow-mediated vasodilation
GTN 5 glyceryl trinitrate
HbA1c 5 glycosylated hemoglobin
HDL 5 high density lipoprotein
LDL 5 low density lipoprotein
L-NMMA 5 NG-monomethyl-L-arginine
NO 5 nitric oxide
NOS 5 nitric oxide synthase
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reactive hyperemia (409 6 59% vs. 463 6 49%, p 5 NS)
were not different between smokers and nonsmokers.
Effects of BH4 on systemic hemodynamic data. Basal
plasma levels of BH4 were not different between smokers
and nonsmokers (Table 1). Sapropterin administration in-
creased plasma levels of BH4 by threefold at 3 h, which
returned to the baseline at 24 h in smokers and nonsmokers
in a similar manner (Table 1). Oral sapropterin administra-
tion did not alter blood pressure and heart rate (Table 1).
Effects of BH4 on vascular function. The baseline vessel
diameter of the brachial artery was not altered by BH4 in
smokers and nonsmokers (Table 1). In smokers, sapropterin
significantly restored FMV during reactive hyperemia and
endothelium-dependent vasodilation to the near-normal
level and returned to the baseline at 24 h (p , 0.0001 by
post hoc analysis), although FMV in nonsmokers was not
altered by BH4 (p 5 NS; p 5 0.001 for the interactions by
ANOVA) (Fig. 1, top). The magnitude of reactive hyper-
emia (smokers: before test 409 6 59%; at 3 h 518 6 64%;
at 24 h 471 6 34%, p 5 NS—nonsmokers: before test
463 6 49%; at 3 h 429 6 42%; at 24 h 422 6 23%, p 5
NS—smokers vs. nonsmokers, p 5 NS) or GTN-induced
endothelium-independent vasodilation (Fig. 1, bottom) was
not different between smokers and nonsmokers and was not
altered by sapropterin.
Effects of NOS inhibition on the effects of BH4 in
smokers (Fig. 2). Before sapropterin, local infusion of
L-NMMA into the brachial artery did not affect blood
pressure, heart rate, baseline vessel size (Table 2), the
magnitude of reactive hyperemia (before test 388 6 75%;
after test 395 6 25%, p 5 NS) or GTN-induced vasodila-
tion, but it significantly decreased FMV (p 5 0.0008 by
post hoc analysis) (Fig. 2, top). Pretreatment with
L-NMMA completely abolished the increase in FMV
induced by sapropterin (p 5 0.002 for the interactions by
ANOVA) (Fig. 2, top), but did not affect GTN-induced
vasodilation (Fig. 2, bottom) or the magnitude of reactive
hyperemia (before test 395 6 25%; at 3 h 438 6 74%, p 5
NS).
Figure 1. Effects of oral sapropterin hydrochloride, an active
analogue of tetrahydrobiopterin, on flow-mediated (top) and
GTN-induced (bottom) vasodilation in smokers and nonsmokers.
Flow-mediated vasodilation of the brachial artery at baseline was
significantly smaller in smokers (p 5 0.0002). In smokers, saprop-
terin significantly augmented FMV (p , 0.0001 by post hoc
analysis) but did not affect it in nonsmokers (smokers vs. non-
smokers, p 5 0.001 for the interactions by ANOVA). Glyceryl
trinitrate–induced vasodilation was not altered by sapropterin in
smokers and nonsmokers.
Table 1. Plasma Tetrahydrobiopterin (BH4) Concentration, Baseline Vessel Diameter and Systemic Hemodynamic Data Before and
After BH4 Administration
Before 3 h 24 h p Value
Smokers vs.
Nonsmokers
BH4 concentration (ng/ml)
Smokers 2.4 6 0.2 8.0 6 0.9 2.6 6 0.3 , 0.0001
NS
Nonsmokers 2.7 6 0.2 11.2 6 2.6 2.8 6 0.1 , 0.0001
Vessel diameter (mm)
Smokers 4.4 6 0.1 4.5 6 0.1 4.5 6 0.2 NS
NS
Nonsmokers 4.7 6 0.2 4.6 6 0.2 4.6 6 0.2 NS
Blood pressure (mm Hg)
Smokers 113 6 3/70 6 3 110 6 4/68 6 4 115 6 3/71 6 3 NS
NS
Nonsmokers 112 6 2/70 6 2 110 6 5/70 6 3 112 6 4/67 6 2 NS
Heart rate (beats/min)
Smokers 71 6 6 70 6 5 68 6 2 NS
NS
Nonsmokers 69 6 7 70 6 5 70 6 2 NS
Data are expressed as the mean value 6 SEM.
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DISCUSSION
The salient findings of this study are 1) impaired
endothelium-dependent vasodilation in long-term smokers
was improved by supplementation with BH4; and 2) an
inhibitor of NOS completely abolished the vasodilatory
effects of BH4.
Endothelial dysfunction in smokers. To assess endothe-
lial function, we measured FMV of the brachial artery by
high resolution ultrasonography. As shown in Figure 2,
FMV was abolished after L-NMMA infusion, supporting
the notion that NO is responsible for FMV of the brachial
artery (12). In agreement with previous observations (13–
15), we found that FMV was impaired in smokers whose
smoking status was verified by plasma cotinine. Because we
enrolled subjects without other coronary risk factors and age
was matched, smoking could be solely responsible for
impaired FMV in smokers. In the present study, the
increases in blood flow during reactive hyperemia were
similar between smokers and nonsmokers, indicating that
the amount of shear stress to the brachial artery during
reactive hyperemia was comparable. In addition, we found
no difference in GTN-induced vasodilation, a measure of
endothelium-independent vascular function, between the
two groups. Collectively, the impaired FMV in smokers
could be attributed to endothelial dysfunction, but not to
the difference in the amount of shear stress or in the
reactivity of vascular smooth muscle cells. The precise
mechanisms of smoking-related endothelial dysfunction are
unknown and may be multifactorial; it may be caused by
decreased endothelial NO formation (14,15) or by increased
inactivation by reactive oxygen species such as superoxide
anion (14,16).
Effects of BH4 on endothelial function. Tetrahydrobiop-
terin augments NO formation and inhibits superoxide
production from NOS in vitro (3,4). It has been suggested
that oxidative stress oxidizes intracellular BH4 to dihydro-
biopterin, an inactive form of biopterin, in endothelial cells
(1,3). Accordingly, we hypothesized that the decreased
bioactivity of NO in smokers may be attributed to the
relative deficiency of BH4. To test this hypotheses, we
administered BH4 into smokers and examined endothelial
function. Administration of BH4 restored FMV only in
smokers. Furthermore, pretreatment with an NOS inhibitor
completely abolished the vasodilatory effects of BH4, sug-
gesting that BH4 may have augmented endothelial NO
production during shear stimuli in smokers. Although the
basal and postload plasma levels of BH4 were comparable
between smokers and nonsmokers, it is possible that BH4
within the endothelium may be deficient, especially during
shear stimulation in smokers.
Study limitations. In this study, we examined endothelial
function in the brachial artery but not in the coronary artery,
so the clinical significance of the study remains to be
Figure 2. Effects of pretreatment with L-NMMA, a NOS inhib-
itor, on BH4-induced vasodilation in smokers. Infusion of
L-NMMA into the brachial artery significantly decreased FMV in
smokers (top) (p 5 0.0008 by post hoc analysis), but did not affect
GTN-induced vasodilation (bottom). The increase (top) (p 5
0.0007 by post hoc analysis) in FMV induced by sapropterin 3 h
after administration was abolished by pretreatment with
L-NMMA (before vs. after sapropterin, p 5 0.002 for the
interactions by ANOVA).
Table 2. Baseline Vessel Diameters and Systemic Hemodynamic Data Before and After L-NMMA Infusion in the Presence or
Absence of Tetrahydrobiopterin
BH4 (2) BH4 (1)
Effects
of BH4
Before
L-NMMA
After
L-NMMA
p
Value
Before
L-NMMA
After
L-NMMA
p
Value
Vessel diameter (mm) 4.6 6 0.1 4.7 6 0.2 NS 4.9 6 0.3 4.8 6 0.3 NS NS
Blood pressure (mm Hg) 115 6 3/69 6 2 112 6 3/71 6 3 NS 111 6 7/72 6 4 109 6 4/71 6 5 NS NS
Heart rate (beats/min) 75 6 3 72 6 5 NS 68 6 5 70 6 5 NS NS
Data are expressed as the mean value 6 SEM.
BH4 5 tetrahydrobiopterin; L-NMMA 5 NG-monomethyl-L-arginine.
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determined. The relevance of endothelial function in the
brachial artery to coronary vascular reactivity in humans
exists; it has been shown that endothelial function is
impaired not only in the coronary artery but also in the
brachial artery in patients with coronary artery disease
(17,18). The number of subjects enrolled in this study was
relatively small.
Previous studies demonstrated that exogenous adminis-
tration of BH4 restores impaired NO bioactivity in hyper-
cholesterolemic humans (5) and hypertensive rats (6), in
which overproduction of oxygen-derived free radicals as well
as impaired NO bioactivity has been reported (2). Thus,
biologic depletion of BH4 in the endothelium may be
present not only in smokers but also in patients with other
coronary risk factors. Orally active sources of BH4 would be
a novel therapeutic tool for endothelial dysfunction in
humans.
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